Bicara Therapeutics: 1500mg Ficerafusp Alfa + Pembrolizumab Shows Estimated 31% 3‑Year OS in 1L R/M HPV‑Negative HNSCC
Bicara Therapeutics announced that a combination of 1500mg weekly ficerafusp alfa and pembrolizumab demonstrated an estimated 31% overall survival at three years in patients with 1L R/M HPV-Negative HNSCC, approximately double the retrospective standard-of-care with pembrolizumab alone. The treatment showed deep, durable responses driven by TGF-β inhibition, with increasing complete response rates and deep response percentages across higher ficerafusp alfa dosages. The company is advancing with a Phase 3 study and planning a future maintenance regimen.
Bicara Therapeutics (BCAX) CEO sells 15K shares and exercises options
Bicara Therapeutics Inc.'s CEO, Claire Mazumdar, sold 15,000 shares of common stock at an average price around $20 per share and simultaneously exercised options to acquire 15,000 shares at $3.7898 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. Following these moves, Mazumdar still directly holds 377,152 shares of common stock and retains options for an additional 146,107 shares, indicating continued significant equity exposure.
Bicara Therapeutics Inc. - Common Stock (Nasdaq:BCAX) Stock Quote
This article provides a stock quote and recent news for Bicara Therapeutics Inc. (Nasdaq: BCAX). It highlights the current stock price, recent performance metrics, and a list of news headlines, including financial results, insider filings, and business updates related to the company's oncology drug development.
Bicara Therapeutics (BCAX) executive sells 12,500 shares under plan
Bicara Therapeutics President and COO Ryan Cohlhepp sold 12,500 shares of common stock at a weighted average price of $20.2919 per share and exercised options for 8,000 shares at $3.7898 per share on May 15, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these sales and exercises, Cohlhepp holds 191,641 direct common stock shares and 101,334 stock options.
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock
Bicara Therapeutics President and COO Ryan Cohlhepp sold 12,500 shares of the company's common stock for over $253k on May 15, 2026, while also acquiring 8,000 shares through option exercises. These transactions were executed under a Rule 10b5-1 trading plan. The article also mentions the stock's recent performance, an EPS miss, and analyst ratings from Citizens and Stifel.
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics has announced an inducement grant to Christopher Sarchi, its new Chief Commercial Officer, under Nasdaq Listing Rule 5635(c)(4). This grant includes a non-qualified stock option to purchase 282,240 shares of common stock at an exercise price of $22.58 per share, vesting over approximately four years. The award serves as a material inducement for his employment, approved by the compensation committee and granted outside of stockholder-approved plans.
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics is progressing with its lead cancer drug candidate, ficerafusp alfa, for head and neck cancer, with pivotal data expected in mid-2026. The drug, a bifunctional antibody targeting EGFR and TGF-beta, has shown promising deep responses, including a 21% complete response rate and significant tumor reductions in clinical data. The company has secured its cash runway into 2029, supporting the ongoing Phase 3 trial, which is currently randomizing patients 2-to-1 to ficerafusp alfa plus pembrolizumab versus pembrolizumab monotherapy, focusing on HPV-negative head and neck cancer.
Bicara Therapeutics Inc. - Common Stock (NQ: BCAX)
This page provides recent news headlines and company updates for Bicara Therapeutics Inc. (NASDAQ: BCAX). Key topics include progress on their lead cancer drug candidate, ficerafusp alfa, ahead of pivotal data in mid-2026, Q1 2026 earnings reports, insider stock transactions, and announcements regarding inducement grants and public offerings. The company is actively involved in clinical development and financial activities to support its therapeutic pipeline.
Number of shareholders of Bicara Therapeutics Inc. – NASDAQ:BCAX
This article provides details on the number of shareholders for Bicara Therapeutics Inc. (NASDAQ: BCAX) and is presented by TradingView. It includes basic financial information, market data, and links to various TradingView products and community features related to stock analysis.
BCAX: Ficerafusp alfa delivers unprecedented durability in head and neck cancer, with pivotal data due mid-2025
Bicara Therapeutics' Ficerafusp alfa is
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant to Christopher Sarchi, its new Chief Commercial Officer, effective May 8, 2026. He received stock options for 282,240 shares with an exercise price of $22.58, vesting over four years. This grant was made under Bicara’s 2026 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4). The biopharmaceutical company is actively developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, targeting EGFR and TGF-b. This news follows several other recent corporate updates for Bicara Therapeutics, including earnings reports and presentations at a major healthcare conference.
New Bicara commercial chief lands option on 282,240 shares
Bicara Therapeutics has granted its new Chief Commercial Officer, Christopher Sarchi, an inducement stock option for 282,240 shares at an exercise price of $22.58. The grant, made under the company's 2026 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), is designed to vest over four years and three months. This aligns Sarchi's incentives with shareholder value and serves as a material inducement for his employment.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant to Christopher Sarchi, its new Chief Commercial Officer, under its 2026 Inducement Plan. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares at $22.58 per share, vesting over approximately four years. This grant was approved by Bicara's compensation committee as a material inducement for his employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (BCAX) CMO awarded 85,000 options at $22.58 strike
Bicara Therapeutics Inc. (BCAX) Chief Medical Officer, William Schelman, was granted 85,000 stock options at an exercise price of $22.58 per share, expiring on May 8, 2036. These options will vest in sixteen equal quarterly installments following May 8, 2026, contingent on his continued service. This award is a routine compensation-related grant rather than an open-market trade.
Bicara Therapeutics (BCAX) CMO reports 175,000-share stock option holdings
Bicara Therapeutics Inc.'s Chief Medical Officer, William Schelman, has reported initial holdings of stock options totaling 175,000 shares. These options are divided into two grants with exercise prices of $16.76 and $16.61 per share, and they are subject to time-based vesting schedules contingent on his continued service. The report, filed on a Form 3, details the expiration dates and vesting timelines for both option grants.
Bicara Therapeutics Inc. reports durable responses for ficerafusp alfa plus pembrolizumab in HPV negative HNSCC
Bicara Therapeutics Inc. has reported positive clinical outcomes for its combination therapy of ficerafusp alfa and pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). Newly published data in the Journal of Clinical Oncology indicate deep and lasting responses, along with promising survival results. These findings suggest a significant advancement in targeted treatment strategies for this patient population with high unmet medical needs.
Citizens reiterates Bicara Therapeutics stock rating on trial progress
Citizens reiterated a Market Outperform rating and $31.00 price target for Bicara Therapeutics (NASDAQ: BCAX) following the company's Q1 2026 financial results and ongoing clinical trial updates. Despite an earnings miss in Q1, the company maintains a strong cash position and expects key data readouts in 2026 and 2027, with Wall Street analysts largely bullish on its prospects. Stifel also adjusted its price target slightly while maintaining a Buy rating, anticipating new data from upcoming ASCO presentations.
Bicara Therapeutics Q1 Loss Widens
Bicara Therapeutics reported a wider loss in the first quarter of fiscal year 2026 compared to the previous year, with a net loss of $25.2 million. The company's basic and diluted net loss per share were both -$0.82. However, Bicara Therapeutics' sales for the quarter saw a significant increase, rising to $650,000 from $400,000 year-over-year.
Bicara Therapeutics Q1 2026 Loss Widens 40.9% Beyond Estimates
Bicara Therapeutics Inc. (NASDAQ:BCAX) reported a Q1 2026 loss of $0.93 per share, significantly wider than the analyst consensus of $0.66, representing a 40.9% miss. The biotechnology company posted a net loss of $56.2M, with the loss per share worsening by 36.8% compared to Q1 2025. Despite these results, Wall Street analysts maintain a positive outlook on the company's long-term prospects due to its pipeline potential.
Cancer biotech Bicara raises $161.8M, cash into 2029 as trials advance
Bicara Therapeutics reported Q1 2026 financial results, highlighting strong progress in its ficerafusp alfa clinical trials, particularly for HPV-negative head and neck cancer. The company secured $161.8 million in net proceeds from a public offering, boosting its cash reserves to $539.8 million, which is expected to fund operations into the first half of 2029. Key upcoming milestones include an interim analysis for its pivotal FORTIFI-HN01 trial in mid-2027 and presentations of long-term Phase 1b data at ASCO 2026.
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics announced its financial results for the first quarter ended March 31, 2026, showcasing strong progress in its clinical trials for ficerafusp alfa, particularly in HPV-negative head and neck cancer. Key highlights include plans to initiate a new randomized clinical study in Q3 2026, upcoming data presentations at ASCO 2026, and strategic executive appointments aimed at advancing towards commercialization. Financially, the company reported $539.8 million in cash, cash equivalents, and marketable securities, expecting to fund operations into the first half of 2029.
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics announced its Q1 2026 financial results, highlighting strong progress in the development of ficerafusp alfa, particularly in HPV-negative head and neck cancer. The company plans to initiate a new randomized clinical study in Q3 2026 and will present long-term follow-up data at ASCO 2026. Major executive changes were also announced, including a new Chief Medical Officer and Chief Commercial Officer, as the company prepares for potential commercialization.
Guggenheim initiates Bicara Therapeutics stock with buy rating
Guggenheim has initiated coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and a $42.00 price target, anticipating approximately 12 months until first phase 3 data for ficerafusp alfa in head and neck squamous cell carcinoma. The firm highlights a $4-5 billion total addressable market and believes Bicara's current valuation implies a 15% market share. Other analysts, including H.C. Wainwright and Citizens, have also expressed confidence in Bicara's prospects, citing its strong financial health and promising clinical trial developments.
Guggenheim initiates Bicara Therapeutics stock with buy rating
Guggenheim has initiated coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and a $42.00 price target, citing the company's lead drug ficerafusp alfa, which addresses a potential $4-5 billion market in first-line head and neck squamous cell carcinoma. The firm highlights Bicara's differentiated features, including a quarterly maintenance dose, and expects positive Phase 3 data next year. This follows other analyst affirmations and strong financial health indicated by recent Q4 2025 results.
Red Tree Group holds 3.17M shares in Bicara Therapeutics (BCAX) — 4.8%
Red Tree GP, LLC, Red Tree Venture Fund I, L.P., and Heath Lukatch filed an amended Schedule 13G/A, disclosing beneficial ownership of 3,170,509 shares, constituting 4.8% of Bicara Therapeutics (BCAX) common stock as of March 31, 2026. This amendment clarifies that Red Tree Fund I directly holds the shares, with Red Tree GP I and Mr. Lukatch holding shared voting and dispositive power. The filing is a passive ownership disclosure and does not indicate a transaction.
Bicara Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview
Bicara Therapeutics Inc. (BCAX) is anticipated to report a loss of 65 cents per share, according to this earnings preview. This brief report from Refinitiv highlights the company's expected financial performance for an upcoming announcement.
FMR LLC reports 2.10M shares in Bicara Therapeutics (NASDAQ: BCAX)
FMR LLC has filed an amendment to its Schedule 13G/A, disclosing beneficial ownership of 2,100,929 shares in Bicara Therapeutics Inc. (BCAX), which represents 3.2% of the company's common stock. The filing indicates FMR LLC holds sole voting power over 2,100,241 shares and sole dispositive power over all 2,100,929 shares. This ownership stake is considered moderate and non-controlling, falling below the 5% threshold typically signaling a more significant position.
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Bicara Therapeutics announced it will report its first quarter 2026 financial results and provide business updates on May 11, 2026, before the market opens. The company will also host a conference call at 8:30 a.m. ET on the same day to discuss these results. Interested parties can register for the call or access a live webcast through the company's investor relations page.
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its first-quarter 2026 financial results and business updates on Monday, May 11, 2026, before market open. The company will host a conference call at 8:30 a.m. ET to discuss these results, with registration and webcast details provided on their investor relations page. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
Bicara Therapeutics' Chief Medical Officer, David Raben, sold 5,500 shares of common stock for $126,000 on April 27, 2026, as part of an option exercise and immediate sale under a Rule 10b5-1 trading plan. This transaction represented 9.05% of Raben's direct holdings, leaving him with an equity stake valued at approximately $1.24 million. Despite the company being unprofitable with a reported net loss of $137.95 million for 2025, its stock is up nearly 30% year-to-date, indicating investor optimism for its future growth in developing bifunctional antibody therapies for solid tumors.
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its first-quarter 2026 financial results and provide business updates on Monday, May 11, 2026, before market open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss these updates. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.
Bicara Therapeutics Inc. schedules May 11 conference for first quarter 2026 financial results
Bicara Therapeutics Inc. has scheduled a conference call for Monday, May 11, to release its first-quarter 2026 financial results and provide a business update. The call will take place at 8:30 AM ET and will be accessible via a live webcast for investors and analysts. The company anticipates offering insights into its recent financial performance and future outlook during this event.
Bicara posts Q1 results May 11, with business update before market
Bicara Therapeutics (Nasdaq: BCAX) is scheduled to report its first-quarter 2026 financial results and business updates on May 11, 2026, before market open. A conference call will follow at 8:30 a.m. ET, with a 30-day webcast replay available. The announcement provides key dates and access details for investors to follow the company's financial and operational progress.
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its first-quarter 2026 financial results and provide business updates before market open on Monday, May 11, 2026. The company will also host a conference call on the same day at 8:30 a.m. ET to discuss the results and updates. Investors can register for the call or access a live webcast via the company's website.
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 5,500 Shares of Stock
Bicara Therapeutics insider David Raben sold 5,500 shares of BCAX stock for $125,840 on April 27th, reducing his stake by 9.05%. This sale occurred under a pre-arranged Rule 10b5-1 plan, following previous sales in March. Analysts currently hold a "Moderate Buy" consensus rating for BCAX with an average target price of $28.00.
BCAX SEC Filings - Bicara Therapeutics 10-K, 10-Q, 8-K Forms
This page on StockTitan provides a comprehensive resource for Bicara Therapeutics (BCAX) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading information. It details the company's financial position, research and development spending, and key clinical events for its lead asset, ficerafusp alfa, for solid tumors. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for each filing.
Bicara Therapeutics CMO David Raben sells $125,830 in shares
David Raben, CMO of Bicara Therapeutics, sold $125,830 worth of company common stock on April 27, 2026, as part of a Rule 10b5-1 trading plan. Concurrently, he acquired an equal number of shares by exercising stock options under the same plan. This transaction comes amidst a strong 48% return for Bicara's stock over the past year and positive analyst outlooks based on promising clinical data and a robust cash position.
Bicara Therapeutics (BCAX) CMO sells 5,500 shares after option exercise
Bicara Therapeutics' Chief Medical Officer, David Raben, exercised stock options for 5,500 shares at $3.7898 each and subsequently sold all 5,500 shares at a weighted average price of $22.8782 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Raben directly holds 55,286 shares of common stock and 41,913 stock options.
5,500-share sale planned by BCAX (BCAX) via Form 144 on 04/27/2026
Bicara Therapeutics Inc. (BCAX) has filed a Form 144, indicating a planned sale of 5,500 shares of common stock on April 27, 2026, following the exercise of stock options. The sale is to be handled by UBS Financial Services Inc. for cash. The filing also detailed prior sales by David Raben in March 2026, including 200 shares, 16,300 shares, and 5,500 shares on different dates.
Bicara Therapeutics (BCAX) details 2026 vote on directors and KPMG
Bicara Therapeutics (BCAX) will hold its 2026 annual shareholder meeting virtually on June 9, 2026. Shareholders will vote on the election of two Class II directors and the ratification of KPMG LLP as the independent auditor for 2026. The board of directors will be reduced from ten to nine members, with Nils Lonberg, Ph.D., not seeking re-election.
Certain Stock Option of Bicara Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 26-APR-2026.
Certain stock options of Bicara Therapeutics Inc. are under a lock-up agreement set to expire on April 26, 2026. The lock-up period began on February 24, 2026, and covers stock options held by directors and executive officers for 61 days. Morgan Stanley & Co. LLC, TD Securities (USA) LLC, and BofA Securities, Inc. retain the sole discretion to release these options earlier.
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep sold 9,200 shares of the company's stock on April 21st for $211,600, reducing his holdings by 5.95%. This transaction was part of a pre-arranged Rule 10b5-1 trading plan, with previous sales also occurring in March and January. The stock was trading up by approximately 2.3% at $23.63, while analysts maintain a "Moderate Buy" rating with a consensus target price of $28.00.
Bicara Therapeutics CFO Hyep sells $211k in stock
Bicara Therapeutics Inc.'s CFO, Hyep Ivan, sold 9,200 shares of company stock for a total of $211,613 on April 21, 2026, executed under a Rule 10b5-1 trading plan. This sale occurred as the stock neared its 52-week high, with InvestingPro indicating it might be overvalued. Concurrently, Mr. Hyep had previously acquired the shares by exercising stock options, and the company recently reported strong Q4 2025 financial results and positive clinical data, leading analysts to maintain 'Market Outperform' and 'Buy' ratings with raised price targets.
Bicara Therapeutics CFO Hyep sells $211k in stock
Bicara Therapeutics CFO Hyep Ivan sold 9,200 shares of the company's common stock for $211,613 on April 21, 2026, under a Rule 10b5-1 trading plan. This sale occurred near the stock's 52-week high after a significant 71% return over the past year. Prior to the sale, Hyep exercised stock options and still holds a substantial number of shares and derivative interests, while the company has reported strong Q4 2025 results and received positive analyst ratings.
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity
Bicara Therapeutics Inc.'s Chief Financial Officer, Hyep Ivan, exercised stock options and sold the resulting shares in a coordinated transaction. On April 21, 2026, he exercised options for 9,200 shares at $3.7898 each and then sold those 9,200 shares in open-market trades at a weighted-average price of $23.0015 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025.
BCAX (BCAX) Form 144 shows option exercise and multiple insider sales
Bicara Therapeutics (BCAX) filed Form 144 notices for proposed sales of Common Stock, detailing an option exercise of 9,200 shares on April 21, 2026, and several past sales by an individual shareholder, Ivan Hyep. The filing, considered procedural, documents these transactions and their associated proceeds, with the largest past sale being 13,555 shares on March 3, 2026, for $246,909.75.
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares
Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares of BCAX stock for $354,150 on April 20th, reducing her ownership by 3.98%. This sale follows earlier sales in March totaling 60,000 shares, indicating significant insider selling. Despite this, analysts maintain a "Moderate Buy" consensus rating with an average price target of $28.00, while the stock trades near its 12-month high.
Bicara Therapeutics (BCAX) CEO sells 15K shares, exercises 37,760 options
Bicara Therapeutics Inc. CEO Claire Mazumdar reported exercising options to acquire 37,760 shares of common stock and simultaneously selling 15,000 shares in the open market at a weighted average price of $23.6097. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, Mazumdar directly owns 362,152 shares of Bicara common stock.
Bicara Therapeutics CEO Mazumdar sells $354k in stock
Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares of the company's stock for over $354,000, executed under a Rule 10b5-1 trading plan. This sale occurred while the stock has surged 93% over the past year, with InvestingPro suggesting it may be overvalued. Concurrently, Ms. Mazumdar acquired 37,760 shares through stock option exercises.
